Systemic corticosteroid monotherapy has no benefit for acute rhinosinusitis
Systemic corticosteroid monotherapy of prednisone is not effective for patients with acute rhinosinusitis, according to a study published in the August 7 issue of the Canadian Medical Association Journal.
Systemic corticosteroid monotherapy of prednisone is not effective for patients with acute rhinosinusitis, according to a study published in the August 7 issue of the Canadian Medical Association Journal.
Roderick P. Venekamp and colleagues conducted a block-randomized, double-blind, placebo-controlled clinical trial at 54 primary care practices in the Netherlands over a span of 3 years.
Of the 174 patients included in the trial, those with facial pain or pressure on day 7 were 62.5% in the prednisone group and 55.8% in the placebo group. “The groups were similar with regard to the decrease over time in the proportion of patients with total symptoms and health-related quality of life,” the researchers wrote.
“Our study results indicate that the anti-inflammatory effect of corticosteroids seems to be of no benefit in the broad population of patients with clinically diagnosed acute rhinosinusitis,” the researchers added.
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More
